EMA starts review of Ixchiq (live attenuated chikungunya vaccine)

View source ↗

Summary

EMA has started a regulatory review of Ixchiq, a live attenuated chikungunya vaccine, and it should not be used in people aged 65 years and older during the ass…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chikungunya

Drugs mentioned

• Ixchiq

Snippet

Vaccine must not be used in people 65 years and above while review is underway